{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T02:23:24Z","timestamp":1743042204038,"version":"3.40.3"},"publisher-location":"New York, NY","reference-count":24,"publisher":"Springer US","isbn-type":[{"type":"print","value":"9781071636817"},{"type":"electronic","value":"9781071636824"}],"license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024]]},"DOI":"10.1007\/978-1-0716-3682-4_32","type":"book-chapter","created":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T12:11:15Z","timestamp":1706184675000},"page":"317-324","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Design an Intervention Study"],"prefix":"10.1007","author":[{"given":"Jun","family":"Ishizaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,26]]},"reference":[{"key":"32_CR1","volume-title":"Designing clinical research","author":"SR Cummings","year":"2013","unstructured":"Cummings SR, Grady D, Hulley SB (2013) Designing a randomized blinding trial. In: Hulley SB, Cummings SR, Browner WS, Grady DG, Newman TB (eds) Designing clinical research, 4th edn. Lippincott Williams & Wilkins\/Wolters Kluwer Health, Philadelphia","edition":"4"},{"key":"32_CR2","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1186\/s13063-017-2134-x","volume":"18","author":"AA den Broeder","year":"2017","unstructured":"den Broeder AA, Verhoef LM, Fransen J et al (2017) Ultra-low dose of rituximab in rheumatoid arthritis: study protocol for a randomised controlled trial. Trials 18:403","journal-title":"Trials"},{"key":"32_CR3","volume-title":"Guideline for good clinical practice E6 (R2). ICH harmonized tripartite guideline","author":"International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use","year":"2016","unstructured":"International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (2016) Guideline for good clinical practice E6 (R2). ICH harmonized tripartite guideline. ICH, Geneva"},{"key":"32_CR4","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.3899\/jrheum.110188","volume":"38","author":"J Karsh","year":"2011","unstructured":"Karsh J, Keystone EC, Haraoui B et al (2011) Canadian recommendations for clinical trials of pharmacologic interventions in rheumatoid arthritis: inclusion criteria and study design. J Rheumatol 38:2095\u20132104","journal-title":"J Rheumatol"},{"key":"32_CR5","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ et al (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62:2569\u20132581","journal-title":"Arthritis Rheum"},{"key":"32_CR6","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/j.jclinepi.2007.02.006","volume":"60","author":"GF Borm","year":"2007","unstructured":"Borm GF, Fransen J, Lemmens WA (2007) A simple sample size formula for analysis of covariance in randomized clinical trials. J Clin Epidemiol 60:1234\u20131238","journal-title":"J Clin Epidemiol"},{"key":"32_CR7","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1002\/sim.5352","volume":"31","author":"S Teerenstra","year":"2012","unstructured":"Teerenstra S, Eldridge S, Graff M et al (2012) A simple sample size formula for analysis of covariance in cluster randomized trials. Stat Med 31:2169\u20132178","journal-title":"Stat Med"},{"key":"32_CR8","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.jclinepi.2014.02.001","volume":"67","author":"E Mathieu","year":"2014","unstructured":"Mathieu E, Herbert RD, McGeechan K et al (2014) A theoretical analysis showed that blinding cannot eliminate potential for bias associated with beliefs about allocation in randomized clinical trials. J Clin Epidemiol 67:667\u2013671","journal-title":"J Clin Epidemiol"},{"key":"32_CR9","first-page":"528","volume":"20","author":"P Tugwell","year":"1993","unstructured":"Tugwell P, Boers M (1993) OMERACT conference on outcome measures in rheumatoid arthritis clinical trials: introduction. J Rheumatol 20:528\u2013530","journal-title":"J Rheumatol"},{"key":"32_CR10","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1002\/art.39945","volume":"69","author":"ME Mack","year":"2017","unstructured":"Mack ME, Hsia E, Aletaha D (2017) Comparative assessment of the different American College of Rheumatology\/European League Against Rheumatism remission definitions for rheumatoid arthritis for their use as clinical trial end points. Arthritis Rheumatol 69:518\u2013528","journal-title":"Arthritis Rheumatol"},{"key":"32_CR11","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1186\/1745-6215-14-324","volume":"14","author":"JJ Kirkham","year":"2013","unstructured":"Kirkham JJ, Boers M, Tugwell P et al (2013) Outcome measures in rheumatoid arthritis randomised trials over the last 50 years. Trials 14:324","journal-title":"Trials"},{"key":"32_CR12","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1136\/ard.2008.091454","volume":"67","author":"D Aletaha","year":"2008","unstructured":"Aletaha D, Landewe R, Karonitsch T et al (2008) Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR\/ACR collaborative recommendations. Ann Rheum Dis 67:1360\u20131364","journal-title":"Ann Rheum Dis"},{"key":"32_CR13","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/ncprheum0948","volume":"4","author":"WD Schwieterman","year":"2008","unstructured":"Schwieterman WD (2008) Issues in the design of new clinical trials for rheumatoid arthritis therapeutics. Nat Clin Pract Rheumatol 4:641\u2013648","journal-title":"Nat Clin Pract Rheumatol"},{"key":"32_CR14","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/art.1780380602","volume":"38","author":"DT Felson","year":"1995","unstructured":"Felson DT, Anderson JJ, Boers M et al (1995) American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38:727\u2013735","journal-title":"Arthritis Rheum"},{"key":"32_CR15","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/art.1780380107","volume":"38","author":"ML Prevoo","year":"1995","unstructured":"Prevoo ML, van \u2018t Hof MA, Kuper HH et al (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44\u201348","journal-title":"Arthritis Rheum"},{"key":"32_CR16","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1093\/rheumatology\/keg072","volume":"42","author":"JS Smolen","year":"2003","unstructured":"Smolen JS, Breedveld FC, Schiff MH et al (2003) A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 42:244\u2013257","journal-title":"Rheumatology (Oxford)"},{"key":"32_CR17","doi-asserted-by":"publisher","first-page":"R796","DOI":"10.1186\/ar1740","volume":"7","author":"D Aletaha","year":"2005","unstructured":"Aletaha D, Nell VP, Stamm T et al (2005) Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 7:R796\u2013R806","journal-title":"Arthritis Res Ther"},{"key":"32_CR18","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1136\/ard.2011.149765","volume":"70","author":"DT Felson","year":"2011","unstructured":"Felson DT, Smolen JS, Wells G et al (2011) American College of Rheumatology\/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 70:404\u2013413","journal-title":"Ann Rheum Dis"},{"key":"32_CR19","first-page":"74","volume":"82","author":"P Studenic","year":"2023","unstructured":"Studenic P, Aletaha D, de Wit M et al (2023) American College of Rheumatology\/EULAR remission criteria for rheumatoid arthritis: 2022 revision. Arthritis Rheumatol 82:74\u201380","journal-title":"Arthritis Rheumatol"},{"key":"32_CR20","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S0950-3579(96)80043-4","volume":"10","author":"DM Van der Heijde","year":"1996","unstructured":"Van der Heijde DM (1996) Plain x-rays in rheumatoid arthritis: overview of scoring methods, their reliability and applicability. Baillieres Clin Rheumatol 10:435\u2013453","journal-title":"Baillieres Clin Rheumatol"},{"key":"32_CR21","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1177\/028418517701800415","volume":"18","author":"A Larsen","year":"1977","unstructured":"Larsen A, Dale K, Eek M (1977) Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn (Stockh) 18:481\u2013491","journal-title":"Acta Radiol Diagn (Stockh)"},{"key":"32_CR22","first-page":"789","volume":"9","author":"JF Fries","year":"1982","unstructured":"Fries JF, Spitz PW, Young DY (1982) The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol 9:789\u2013793","journal-title":"J Rheumatol"},{"key":"32_CR23","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","volume":"30","author":"JE Ware Jr","year":"1992","unstructured":"Ware JE Jr, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30:473\u2013483","journal-title":"Med Care"},{"key":"32_CR24","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A et al (2011) Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 20:1727\u20131736","journal-title":"Qual Life Res"}],"container-title":["Methods in Molecular Biology","Rheumatoid Arthritis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-3682-4_32","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T12:12:31Z","timestamp":1706184751000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-3682-4_32"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"ISBN":["9781071636817","9781071636824"],"references-count":24,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-3682-4_32","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"type":"print","value":"1064-3745"},{"type":"electronic","value":"1940-6029"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"26 January 2024","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}